Side-by-side · Research reference
HumaninvsMatrixyl
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/52 cited
BAnimal-MechanisticHUMAN-REVIEWED9/39 cited
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
Matrixyl
Cosmeceutical Pentapeptide · Topical Anti-Aging
Topical · Dermal · Twice Daily
01Mechanism of Action
Parameter
Humanin
Matrixyl
Primary target
Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022Lue 2021
Dermal fibroblastsPaccola 2025
Pathway
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling
Downstream effect
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025
Feedback intact?
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
—
Origin
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022
Antibody development
Not reported in animal models
—
02Dosage Protocols
Parameter
Humanin
Matrixyl
Standard experimental dose (HNG)
4 mg/kg IP (rat)
Most common dose in rodent models.
—
Ex vivo bone culture
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
—
Frequency
Daily (IP)
—
Duration
8–12 weeks in animal studies
8–12 weeks minimum for visible effect
Collagen synthesis requires sustained application.
Human data
None — no clinical trials reported
—
Analog (HNG)
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
—
Formulation concentration
—
0.5–5% in topical vehicle
Common cosmeceutical range; higher concentrations in clinical formulations.
Application frequency
—
Twice daily (AM/PM)
Standard cosmeceutical protocol.
Vehicle
—
Serum, cream, or emulsion base
Lipophilic carriers enhance penetration.
03Metabolic / Fat Loss Evidence
Parameter
Humanin
Matrixyl
Direct fat loss evidence
None
—
Mechanism overlap
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
—
04Side Effects & Safety
Parameter
Humanin
Matrixyl
Animal model safety
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
—
Human safety data
None — no clinical trials
—
Theoretical fibrillation risk
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
—
Injection site reaction
Not reported in animal studies (IP route)
—
Reproductive safety
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
—
Irritation
—
Mild erythema, pruritus in sensitive skin (rare)
Allergic reaction
—
Contact dermatitis (uncommon)
Systemic absorption
—
Negligible — topical application only
Absolute Contraindications
Humanin
- ·Unknown — no human data
Matrixyl
- ·Known hypersensitivity to palmitoyl peptides
Relative Contraindications
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
Matrixyl
- ·Active dermatitis or open wounds at application site
05Administration Protocol
Parameter
Humanin
Matrixyl
1. Route (experimental)
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
Wash face with gentle cleanser. Pat dry.
2. Reconstitution
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.
3. Timing
Daily administration in animal studies. Optimal timing not characterized.
Twice daily — morning and evening. Apply before heavier creams or sunscreen.
4. Storage
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.
5. Human use
No FDA approval, no IND, no clinical trials. Experimental research tool only.
—
06Stack Synergy
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling
Matrixyl
+ GHK-Cu
Multi-pathwayMatrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.
- Matrixyl
- 0.5–5% topical serum · AM/PM
- GHK-Cu
- 1–2% topical serum · same application
- Frequency
- Twice daily
- Primary benefit
- Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity